Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Cerity Partners LLC

Cerity Partners LLC reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,401 shares of the company’s stock after selling 2,361 shares during the period. Cerity Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $746,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares during the period. National Pension Service boosted its position in shares of Teva Pharmaceutical Industries by 107.3% during the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $23,115,000. Davidson Kempner Capital Management LP raised its holdings in shares of Teva Pharmaceutical Industries by 152.5% in the 2nd quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock worth $28,689,000 after purchasing an additional 1,066,150 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Trading Up 0.2 %

Shares of TEVA stock opened at $17.83 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The firm has a market capitalization of $20.20 billion, a P/E ratio of -20.98, a price-to-earnings-growth ratio of 1.35 and a beta of 0.79. The firm’s fifty day simple moving average is $17.54 and its 200 day simple moving average is $17.37. Teva Pharmaceutical Industries Limited has a 1 year low of $9.35 and a 1 year high of $19.31.

Wall Street Analyst Weigh In

A number of research firms have commented on TEVA. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.